CGM
The FDA approval closes a gap with competitors Dexcom and Abbott, as well as setting the company up for entry into the Medicare market.
Using devices and systems that have not been authorized by the regulatory agency comes with a risk.
Biolinq's new funding was led by JDRF T1D Fund, Aphelion Capital and LifeSci Venture Partners.
The Eversense Bridge program is geared toward patients with high-deductible insurance plans or plans that don't cover the full cost of Eversense CGM, and allows them to purchase the system for $99.
Users of the Eversense CGM will be able to transfer their data to Glooko's online diabetes management platform.
Dexcom announced a slew of announcements this morning including an integration with Google Fit, a feature that lets users share their readings with 10 people and a technical inquiries feature.
Ascensia will launch a version of POCTech's device this year, then collaborate on co-developing the next generation.
The clearance brings US readers a feature long available in Europe, and paves the way for data plays.
The market comprised $98 million in revenue during 2017, and is beginning to move away from stand-alone devices or apps.
Realtime blood glucose information will allow Livongo's platform to deliver more insights, coaching to people with diabetes.